Business Standard

Glenmark under fire for over pricing, 'misguided' claims of Covid-19 drug

NCP legislator Amol Kolhe's letter to Health Minister Harsh Vardhan triggers the DCGI to seek details from the Mumbai-based drugmaker

Glenmark has completed phase-III clinical studies, with favipiravir in mild-to-moderate Covid-19 patients in India.
Premium

Glenmark has completed phase-III clinical studies, with favipiravir in mild-to-moderate Covid-19 patients in India.

Sohini Das Mumbai
Glenmark, which markets favipiravir under brand Fabiflu for treatment of mild-to-moderate Covid-19 patients, has come under the scanner of ‘the country’s drug regulator over pricing of the drug and claims of its therapeutic efficacy.

The Drug Controller General of India (DCGI) has sent a letter to the Mumbai-based drugmaker seeking clarifications on pricing as well as claims of therapeutic efficacy.

The move was triggered by a letter Nationalist Congress Party legislator Amol Kolhe wrote addressed to the health minister.

The DCGI had given emergency use authorisation to favipiravir in the third week of June. It was an expedited approval following

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in